Skip to main content
LPCN
NASDAQ Life Sciences

分析师预测Lipocine Inc.收入暴跌97%，每股亏损61美分

feedReported by Reuters
Sentiment info
Negative
Importance info
7
Price
$8.13
Mkt Cap
$45.137M
52W Low
$2.52
52W High
$12.37
Market data snapshot near publication time

summarizeSummary

分析师预计Lipocine Inc.将面临严重的财务衰退，预计季度收入将下降96.7%至116,000美元，每股亏损61美分，截止日期为2025年12月31日。这种大量的预计收入下滑对于像Lipocine这样的市值公司来说是非常重要的，表明存在重大运营挑战。虽然这些只是估计，但如此激进的预测可能会促使交易者在官方盈利公告发布前调整头寸，预计公告时间大约在3月11日。这个消息增加了最近的财务活动叙事，继公司在2月下旬将其At-The-Market发行扩大至5,000万美元之后。

在该公告发布时，LPCN的交易价格为$8.13，交易所为NASDAQ，所属行业为Life Sciences，市值约为$4513.7万。 52周交易区间为$2.52至$12.37。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed LPCN - Latest Insights

LPCN
Apr 21, 2026, 5:12 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Shareholders to Vote on Significant Increase in Equity Incentive Plan Shares Amidst Financial Challenges
Sentiment: Negative
View Wiseek Article
LPCN
Apr 21, 2026, 5:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Lipocine Seeks Shareholder Approval for Significant Equity Incentive Plan Expansion and Elects New Chairman
Sentiment: Negative
View Wiseek Article
LPCN
Apr 21, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Lipocine Chairman Resigns Citing Differing Views on Strategic Direction
Sentiment: Negative
View Wiseek Article
LPCN
Apr 07, 2026, 6:27 PM EDT
Filing Type: 4
Importance Score:
8
Director John W. Higuchi Buys Additional $81,200 in Lipocine Stock Following Drug Trial Failure
Sentiment: Positive
View Wiseek Article
LPCN
Apr 06, 2026, 7:01 PM EDT
Filing Type: 4
Importance Score:
9
Director Makes Substantial Open Market Purchase Following Recent CEO Buy Amidst Drug Trial Setback
Sentiment: Positive
View Wiseek Article
LPCN
Apr 06, 2026, 6:33 PM EDT
Filing Type: 4
Importance Score:
8
CEO Buys $50K in Shares Following Drug Candidate Failure, Signaling Confidence
Sentiment: Positive
View Wiseek Article
LPCN
Apr 02, 2026, 9:40 AM EDT
Filing Type: 8-K
Importance Score:
8
Lipocine Details Phase 3 PPD Drug Failure, Highlights Subgroup Data for Path Forward
Sentiment: Negative
View Wiseek Article
LPCN
Apr 02, 2026, 9:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Lipocine's Lead PPD Drug Fails Phase 3 Primary Endpoint, Company to Re-evaluate Options
Sentiment: Negative
View Wiseek Article
LPCN
Apr 02, 2026, 8:14 AM EDT
Source: Reuters
Importance Score:
9
Lipocine's PPD Drug Misses Phase 3 Primary Endpoint, Clouding Future Prospects
Sentiment: Negative
View Wiseek Article
LPCN
Mar 10, 2026, 6:13 AM EDT
Filing Type: 8-K
Importance Score:
8
Lipocine Reports Steep 2025 Losses & Revenue Drop, Boosts Cash via ATM, Advances PPD Drug to NDA
Sentiment: Neutral
View Wiseek Article